Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Significant Drop in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 190,290 shares, a decline of 39.0% from the July 30th total of 311,827 shares. Based on an average daily volume of 1,508,069 shares, the short-interest ratio is presently 0.1 days. Approximately 1.5% of the shares of the company are sold short.

Capstone Therapeutics Stock Performance

Shares of NASDAQ CAPS opened at $0.18 on Monday. The company has a market cap of $3.77 million, a price-to-earnings ratio of -0.05 and a beta of -1.52. Capstone Therapeutics has a 12-month low of $0.17 and a 12-month high of $1.57. The company has a current ratio of 0.99, a quick ratio of 0.39 and a debt-to-equity ratio of 0.69. The stock’s 50 day simple moving average is $0.24 and its 200 day simple moving average is $0.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Capstone Therapeutics

A hedge fund recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 2.55% of the company’s stock.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.